FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer


U.S. Food and Drug Administration
FDA approves pembrolizumab with enfortumab vedotin-ejfv
On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (K...





